New induction and postinduction strategies in acute myeloid leukemia

Burnett, Alan Kenneth 2012. New induction and postinduction strategies in acute myeloid leukemia. Current Opinion in Hematology 19 (2) , pp. 76-81. 10.1097/MOH.0b013e3283500a92

Full text not available from this repository.

Abstract

Purpose of review: Improving or replacing the traditional induction (3 + 7) and consolidation (high-dose cytarabine; Ara-C) as the standard of care for acute myeloid leukemia (AML) has proved disappointing. Recent findings: Recent studies have raised the possibility that daunorubicin dose escalation might have the potential to improve survival. Antibody-directed therapy by means of gemtuzumab ozogamicin as an adjunct to induction chemotherapy may yet be a viable option in older patients, and alternative nucleoside analogues in induction could help higher risk subgroups. In consolidation, the number of courses and dose level of Ara-C required are being clarified. New treatments for older patients who will not be subjected to conventional chemotherapy are an active area, but randomized trials have not yet usurped low-dose Ara-C (LDAC). Summary: Recent information in these areas is reviewed.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Lippincott Williams & Wilkins
ISSN:	1065-6251
Last Modified:	25 Jun 2017 03:27
URI:	https://orca.cardiff.ac.uk/id/eprint/28917

Citation Data

Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item